<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03929588</url>
  </required_header>
  <id_info>
    <org_study_id>EYEQUE - 001</org_study_id>
    <nct_id>NCT03929588</nct_id>
  </id_info>
  <brief_title>Study of a Hand-held Device Plus Mobile App Versus Standard Eye Care Devices in Measuring Refractive Error of the Eye</brief_title>
  <official_title>A Clinical Validation Study to Evaluate the Performance of a Hand-held Device Supported by a Mobile Application Compared With Standard Eye Care Diagnostic Devices in Measuring Refractive Error of the Eye</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EyeQue Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EyeQue Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Single-center, open-label, prospective study in healthy volunteers desiring refraction for
      correction of visual acuity to compare a handheld device supported by a mobile application
      with the phoropter and autorefractor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single-center, open-label, prospective study in healthy volunteers desiring refraction for
      correction of visual acuity to compare a handheld device supported by a mobile application
      with the phoropter and autorefractor in male or female subjects 30 to 65 years of age.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All enrolled subjects will have measurements with the phoropter, autorefractor and handheld device plus mobile app.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BVCA utilizing refraction results from handheld device compared to manual refraction methods for the age stratum 45 through 65 years</measure>
    <time_frame>Through study completion, an average of 5 months</time_frame>
    <description>Best-corrected visual acuity (BVCA) utilizing refraction results using the handheld device with supporting application will be compared to standard manual refraction methods (using a phoropter) for the age stratum 45 through 65 years.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>BVCA utilizing refraction results from handheld device compared to automated refraction methods.</measure>
    <time_frame>Through study completion, an average of 5 months</time_frame>
    <description>BVCA utilizing refraction results using the handheld device with supporting application will be compared to automated refraction methods (using an autorefractor).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing similarity of refraction values from the handheld device compared with the phoropter.</measure>
    <time_frame>Through study completion, an average of 5 months</time_frame>
    <description>Assessing similarity of refraction values (sphere, cylinder, axis) from the handheld device with supporting application compared with the phoropter through comparative plots and correlations for the age stratum 30 through 65 years and 45 through 65 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BVCA utilizing refraction results from handheld device compared to manual refraction methods for the age stratum 30 through 65 years.</measure>
    <time_frame>Through study completion, an average of 5 months</time_frame>
    <description>BVCA utilizing refraction results using the handheld device with supporting application will be compared to standard manual refraction methods (using a phoropter) for the age stratum 30 through 65 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessing similarity of refraction values from the handheld device compared with the autorefractor.</measure>
    <time_frame>Through study completion, an average of 5 months</time_frame>
    <description>Assessing similarity of refraction values (sphere, cylinder, axis) from the handheld device with supporting application compared with the autorefractor through comparative plots and correlations for the age stratum 30 through 65 years and 45 through 65 years.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Refractive Errors</condition>
  <condition>Astigmatism</condition>
  <arm_group>
    <arm_group_label>Refraction with a Hand-held Device Supported by Mobile App.</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BCVA with handheld device with app.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual Refraction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BCVA with phoropter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Automated Refraction</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BCVA with autorefractoer</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hand-held device supported by a mobile application</intervention_name>
    <description>Hand-held device supported by a mobile application to obtain refractive error of the eye.</description>
    <arm_group_label>Automated Refraction</arm_group_label>
    <arm_group_label>Manual Refraction</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Phoropter</intervention_name>
    <description>Manual refraction and ETDRS chart</description>
    <arm_group_label>Refraction with a Hand-held Device Supported by Mobile App.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Autorefractor</intervention_name>
    <description>Automated refraction</description>
    <arm_group_label>Refraction with a Hand-held Device Supported by Mobile App.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or Female

          -  Age 30 through 65 years at the time of consent

          -  Binocular vision

          -  Subject desires refraction for correction of visual acuity and vision can be corrected
             in each eye to 20/20 (LogMAR 0.0)

          -  Willing and able to give informed consent and follow all study procedures and
             requirements

          -  Ability to speak and understand the English language

        Exclusion Criteria:

          -  Spherical correction &gt; +8 or &lt; -10

          -  Using anticholinergic medications (including first-generation antihistamines) or other
             medications known to affect visual acuity within the greater of 3 days or 5 half-lives
             prior to enrolling in this study

          -  Using an investigational drug or approved therapy for investigational use within the
             greater of 3 days or 5 half-lives prior to enrolling in this study

          -  Has initiated any new medication in the past 2 weeks that, in the best medical
             judgment of the investigator, would impact their participation in the study or ability
             to use the device

          -  Eye disease, including but not limited to:

               -  Glaucoma (≥ 22 mmHg intraocular pressure)

               -  Cataracts (≥ 1+ nuclear sclerotic cataract, ≥ 1+ cortical, posterior subcapsular
                  cataract [any grade using the Lens Opacities Classification System III])

               -  Macular degeneration (retinal pigmented epithelium mottling and/or any drusen
                  within 500 μm of macula)

               -  Eye infection (corneal ulcer, corneal infiltrates, superficial punctate
                  keratitis)

               -  Keratoconus

               -  Diabetic neuropathy/retinopathy (≥ mild nonproliferative diabetic retinopathy)

               -  Cytomegalovirus retinitis

               -  Color blindness (any color deficiency)

               -  Diabetic macular edema (evidence of fluid)

               -  Amblyopia

               -  Chronic or acute uveitis (cells and/or flare in anterior chamber)

               -  Strabismus (exotropia, esotropia, and hypertropia)

               -  Abnormal astigmatism (mild to severe, &gt; 5 diopters)

               -  Macular hole

          -  Eye surgery within the last 12 months (including Lasik or lens replacement)

          -  Subject does not have the physical dexterity to properly operate the device or the on
             the smartphone in the investigator's opinion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James Peace, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>United Medical Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Carmen Marin</last_name>
    <phone>310-645-4673</phone>
    <email>carmen@drjamespeace.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>United Medical Research Institute</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>April 22, 2019</study_first_submitted>
  <study_first_submitted_qc>April 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2019</study_first_posted>
  <last_update_submitted>November 19, 2019</last_update_submitted>
  <last_update_submitted_qc>November 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>myopia</keyword>
  <keyword>hyperopia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

